CD274 and B-cell chronic lymphocytic leukemia: Similarly, in a mouse model of CLL, Hanna et al. demonstrated that ibrutinib plus antibodies that disrupt the PD-1/PD-L1 axis enhanced CD8+ T cell effector activity [46].